Researchers at the University of California, Davis (“UC Davis”) have developed methods for screening and targeting regions of viral genomes to identify drugs that inhibit the replication of RNA viruses.
RNA-targeted therapies are a drug discovery platform inherently more precise than traditional small-molecule drugs. RNA-targeted therapies are specific and customizable, as Cas proteins can target a virus’ RNA more precisely. Thus, these technologies can access targets previously considered “undruggable”—e.g., certain regions of the SARS-CoV-2 RNA genome.
Researchers at UC Davis have developed screening techniques and molecular medicines to specifically target RNA viruses and inhibit their growth, and have identified accessible regions of viral genomes for targeting. The discovered methods include administering an antisense oligonucleotide (“ASO”)-based drug or a pharmaceutical composition containing an ASO, guide RNAs (“gRNA”) administered via an adeno-associated viral (“AAV”) vector, and an AAV vector that introduces both the Cas nuclease and the gRNA into the cell. This technology provides a method for identifying a gRNA that is either identical to or complementary to an equal-length portion of a sequence of a gene in the SARS-CoV-2 virus genome and targets a Cas nuclease to the sequence of the gene.
This technology is applicable as a therapeutic option for many diseases—including those caused by coronaviruses and other similar types of viruses.
|Patent Cooperation Treaty||Published Application||2021226019||11/11/2021||2020-539|
RNA viruses, coronavirus, molecular medicines, viral genomes, Cas proteins, ASO, gRNA, SARS-CoV-2